Skip to Content
Merck
CN

SML3694

Sigma-Aldrich

FR901464

≥95% (HPLC)

Synonym(s):

(2Z,4S)-4-(acetyloxy)-N-[(2R,3R,5S,6S)-6-[(2E,4E)-5-[(3R,4R,5R,7S)-4,7-dihydroxy-7-methyl-1,6-dioxaspiro[2.5]oct-5-yl]-3-methyl-2,4-pentadien-1-yl]tetrahydro-2,5-dimethyl-2H-pyran-3-yl]-2-Pentenamide, FR 901464, WB 2663B

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C27H41NO8
CAS Number:
Molecular Weight:
507.62
UNSPSC Code:
12352200
NACRES:
NA.77
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

Assay

≥95% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear (Warmed)

shipped in

dry ice

storage temp.

−70°C

Biochem/physiol Actions

Inhibitor of pre-mRNA splicing; potent antitumor agent.

FR901464 is a potent anticancer agent isolated from the culture broth of the bacterium Pseudomonas sp. 2663. The compound binds to the splicing factor 3b complex and inhibits pre-mRNA splicing. FR901464 causes cell cycle arrest at the G1 and G2/M phases.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Meayamycin inhibits pre-messenger RNA splicing and exhibits picomolar activity against multidrug-resistant cells
Molecular Cancer Therapeutics, 8(8), 2308-2318 (2009)
Inhibition of splicing and nuclear retention of pre-mRNA by spliceostatin A in fission yeast
Biochemical and Biophysical Research Communications, 364(3), 573-577 (2007)
Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy
Oncotarget, 10(3), 352-367 (2019)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service